CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.171
Abstract: NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA- approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various… read more here.
Keywords: response; cns metastases; fusion cancer; cancer ... See more keywords
EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.132
Abstract: Abstract BACKGROUND TRK fusions are oncogenic drivers in a variety of tumors, many involving the CNS. Larotrectinib, a selective FDA- and EMA-approved TRK inhibitor, demonstrated a 79% objective response rate (ORR) and a 35.2-month median… read more here.
Keywords: cns tumors; patients primary; fusion; trk fusion ... See more keywords
RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.968
Abstract: TRK fusions are oncogenic drivers of a variety of tumors, many of which can involve the central nervous system (CNS). Larotrectinib is a selective TRK inhibitor FDA-approved for the treatment of TRK fusion cancers (Drilon… read more here.
Keywords: central nervous; patients primary; fusion; trk fusion ... See more keywords
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3165
Abstract: Purpose: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion–positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic… read more here.
Keywords: trk inhibitors; trk fusions; trk fusion; trk ... See more keywords
Abstract CT020: Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct020
Abstract: Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Larotrectinib is a first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved in over 40 countries, including the US,… read more here.
Keywords: response; trk fusion; cancer; patients trk ... See more keywords
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-17-0507
Abstract: Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion-positive cancers. Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited… read more here.
Keywords: kinase; acquired resistance; trk fusion; resistance ... See more keywords
Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3614
Abstract: 3614Background: NTRK gene fusions occur in diverse tumor types in adults and children. The selective TRK inhibitor, larotrectinib, has shown high response rates, durable disease control, and a favo... read more here.
Keywords: quality life; life adults; fusion cancer; children trk ... See more keywords
Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3114
Abstract: 3114 Background: Larotrectinib is a highly selective, CNS-active tropomyosin receptor kinase (TRK) inhibitor that demonstrated rapid and durable responses in three phase I/II single-arm studies of patients (pts) with TRK fusion cancer. In single-arm studies… read more here.
Keywords: trk fusion; therapy; fusion cancer; gmi ... See more keywords
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Endocrinology"
DOI: 10.1530/eje-21-1259
Abstract: Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma… read more here.
Keywords: trk fusion; thyroid carcinoma; fusion positive;
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2020.20045
Abstract: BACKGROUND Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metastasized and progressed. Early evidence indicates that these… read more here.
Keywords: larotrectinib entrectinib; life; trk fusion; larotrectinib ... See more keywords